Ratings by Raymond James (Martin Auster)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/29/2026 | Evommune Inc | EVMN | Downgrade | Outperform (Strong Buy) |
25.18 (11.47) |
-54.45% | Details | |
| 6/8/2026 | Septerna Inc | SEPN | Maintain | Strong Buy (N/A) |
|
Details | ||
| 6/8/2026 | iBio, Inc. | IBIO | New Coverage | Outperform (N/A) |
1.82 (1.45) |
-20.33% | Details | |
| 6/1/2026 | Edgewise Therapeutics | EWTX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 5/26/2026 | BridgeBio Pharma | BBIO | Downgrade | Market Perform (Outperform) |
70.28 (84.12) |
19.69% | Details | |
| 5/26/2026 | Tectonic Therapeutics Inc. | TECX | Upgrade | Strong Buy (Outperform) |
28.52 (30.61) |
7.33% | Details | |
| 4/28/2026 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 4/13/2026 | Equillium | EQ | New Coverage | Strong Buy (N/A) |
1.80 (2.46) |
36.67% | Details | |
| 4/13/2026 | Spyre | SYRE | New Coverage | Strong Buy (N/A) |
51.29 (100.04) |
95.05% | Details | |
| 3/31/2026 | Scholar Rock | SRRK | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/26/2026 | WAVE Life Sciences | WVE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/25/2026 | Maze Therapeutics | MAZE | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/10/2026 | Edgewise Therapeutics | EWTX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/9/2026 | Eupraxia Pharmaceuticals | EPRX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/3/2026 | Scholar Rock | SRRK | Maintain | Strong Buy (N/A) |
|
Details | ||
| 2/26/2026 | Edgewise Therapeutics | EWTX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 2/19/2026 | Eupraxia Pharmaceuticals | EPRX | New Coverage | Strong Buy (N/A) |
8.16 (6.17) |
-24.39% | Details | |
| 2/12/2026 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 1/12/2026 | Alnylam Pharmaceuticals | ALNY | Maintain | Outperform (N/A) |
|
Details | ||
| 1/7/2026 | Evommune Inc | EVMN | New Coverage | Strong Buy (N/A) |
16.08 (25.18) |
56.59% | Details | |
| 12/19/2025 | Septerna Inc | SEPN | New Coverage | Strong Buy (N/A) |
27.54 (33.49) |
21.6% | Details | |
| 12/12/2025 | Phathom Pharmaceuticals | PHAT | New Coverage | Strong Buy (N/A) |
14.55 (11.95) |
-17.87% | Details | |
| 12/8/2025 | Disc Medicine | IRON | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/13/2025 | Maze Therapeutics | MAZE | New Coverage | Outperform (N/A) |
32.56 (28.69) |
-11.89% | Details | |
| 10/31/2025 | Disc Medicine | IRON | Maintain | Strong Buy (N/A) |
|
Details | ||
| 10/30/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Outperform (N/A) |
|
Details | ||
| 10/27/2025 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 10/17/2025 | Ascendis Pharma | ASND | New Coverage | Strong Buy (N/A) |
207.12 (253.42) |
22.35% | Details | |
| 8/7/2025 | Edgewise Therapeutics | EWTX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 8/6/2025 | Scholar Rock | SRRK | Maintain | Strong Buy (N/A) |
|
Details | ||
| 8/1/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Outperform (N/A) |
|
Details | ||
| 7/30/2025 | Alnylam Pharmaceuticals | ALNY | New Coverage | Outperform (N/A) |
324.79 (278.40) |
-14.28% | Details | |
| 7/30/2025 | Cytokinetics | CYTK | Downgrade | Market Perform (Outperform) |
36.63 (80.62) |
120.09% | Details | |
| 7/30/2025 | Edgewise Therapeutics | EWTX | New Coverage | Strong Buy (N/A) |
14.26 (41.60) |
191.73% | Details | |
| 7/30/2025 | BridgeBio Pharma | BBIO | New Coverage | Outperform (N/A) |
46.23 (70.28) |
52.02% | Details | |
| 7/29/2025 | Scholar Rock | SRRK | New Coverage | Strong Buy (N/A) |
37.09 (48.93) |
31.92% | Details |
